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Abstract
As access to antiretroviral treatment in low- and middle-income countries improves, the number of older adults 
(aged ≥ 50 years) living with HIV is increasing. This study compares the adherence to antiretroviral treatment among older 
adults to that of younger adults living in Africa. We searched PubMed, Medline, Cochrane CENTRAL, CINAHL, Google 
Scholar and EMBASE for keywords (HIV, ART, compliance, adherence, age, Africa) on publications from 1st Jan 2000 
to 1st March 2016. Eligible studies were pooled for meta-analysis using a random-effects model, with the odds ratio as the 
primary outcome. Twenty studies were included, among them were five randomised trials and five cohort studies. Overall, 
we pooled data for 148,819 individuals in two groups (older and younger adults) and found no significant difference in adher-
ence between them [odds ratio (OR) 1.01; 95% CI 0.94–1.09]. Subgroup analyses of studies using medication possession 
ratio and clinician counts to measure adherence revealed higher proportions of older adults were adherent to medication 
regimens compared with younger adults (OR 1.06; 95% CI 1.02–1.11). Antiretroviral treatment adherence levels among 
older and younger adults in Africa are comparable. Further research is required to identify specific barriers to adherence 
in the aging HIV affected population in Africa which will help in development of interventions to improve their clinical 
outcomes and quality of life.
Keywords HIV · Adherence · ART  · Africa · Older adults · Systematic review
Introduction
Globally, there are 36.7 million people living with human 
immunodeficiency virus (HIV), of which 69% live in Africa 
[1]. UNAIDS estimated that in 2016 there were 5.8 (5.3–6.2) 
million people aged 50 years and older living with HIV, 
representing 17% of all adults aged 15 years and over living 
with HIV [2]. Their modelling data also predicts that the 
number of older adults living with HIV in low- and middle-
income countries around the world will increase by 47% by 
2020 and most of them will be living in sub-Saharan Africa 
(SSA).
Over the past decade there has been an increase in the 
access to life-prolonging antiretroviral therapy (ART), 
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and factors such as improved HIV surveillance, clinician 
awareness of HIV, advancement of diagnostic techniques 
etc., have led to an increase in people aged 50 years and 
older living with HIV [3, 4]. As life expectancy in Africa 
is lower than developed countries around the world, WHO 
projects in Africa have categorized older adults as people 
aged 50 years and older [5]. This definition of older adults 
for reporting HIV incidence and ART adherence, in low and 
middle income countries, is well documented in the in pub-
lished literature [6, 7].
With the increased life span, ageing population is becom-
ing susceptible to other causes of ill health [8, 9], which in 
turn may affect their adherence to ART. Evidence shows 
that poor immunological response to ART is a surrogate of 
biological ageing [10]. The natural ageing process causes a 
decline in immunocompetence making older adults suscep-
tible to both communicable and non-communicable diseases 
such as diabetes and hypertension when compared to young 
adults [11–13]. Therefore, understanding adherence of older 
adults to ART is paramount to develop strong HIV treatment 
programs.
Optimal adherence has both individual health benefits as 
well as wider public health benefits such as prevention of 
HIV endemic and improvement of mental health [14, 15]. 
Whereas poor adherence leads to incomplete viral suppres-
sion allowing disease progression which ultimately increases 
mortality [16, 17]. In 2014, UNAIDS called for the ambi-
tious 90-90-90 targets with the aim of ending the global 
AIDS epidemic by improving surveillance, ART adherence 
and viral suppression in infected individual [18]. The pro-
gram was aimed to achieve its goals by 2020 and one of the 
targets was to have 90% of all people receiving anti-retrovi-
ral treatment (ART) achieve viral suppression by 2020. This 
target can only be achieved if there is a strong emphasis on 
ART adherence. Despite the growing recognition that older 
people are increasingly infected with HIV [6, 19] and are 
accessing treatment, the literature on ART adherence among 
older adults is limited [20, 21]. This is particularly true in 
SSA where the burden of HIV among older adults is highest, 
and treatment and adherence challenges are greatest due to 
overburdened health services that are not set up to address 
older peoples’ needs.
A recent review has shown that the adherence to ART 
among older adults is higher than that of younger adults in 
developed countries [7]. There are reasons to believe this 
in the context developed countries, where older adults are 
likely to be financially stable and medically aware about 
their health. However, older adults in SSA might experience 
different barriers to adherence when compared to younger 
adults. These might include high rates of poverty, limiting 
money for transport and care [22, 23]; multi-morbidity with 
various chronic diseases leading to poly-pharmacy [24]; 
social isolation [25]; ageism or elder abuse [22]; and little 
understanding among health providers of older persons’ 
needs [22, 24]. Another important determinant of adherence 
in elderly is neurocognitive impairment. It has been shown 
that decline in executive functioning, motor functioning, 
and processing speed leads to suboptimal adherence in older 
adults [26]. Moreover, in high morbidity/mortality and high 
poverty areas, older adults often lose their caregivers and 
must provide care to others while suffering from age-related 
illness and frailty [27, 28]. As a result they may feel lonely, 
disconnected and despondent eventually becoming hopeless 
and demotivated to seek treatment [29, 30]. Depression is a 
surrogate of this sequel which has been shown to be a pre-
dictor for non-adherence (OR 2.54; 95% CI 1.65–3.91) [31].
A critical first step to improving adherence among older 
adults in Africa and thus helping to achieve the 90-90-90 
targets is to understand current levels of treatment adher-
ence. Currently there is no synthesis in the literature on the 
comparison of adherence rates for ART between older and 
younger adults living in Africa. Therefore, we conducted a 
systematic review and meta-analysis to examine adherence 
to ART in Africa among older adults compared to younger 
adults.
Methods
Definitions
For the purposes of this systematic review, we defined ART 
as any combination of antiretroviral therapy. Adherence per-
tains to the correspondence between a patient’s actual medi-
cation use and the regimen prescribed by a health care pro-
vider [32]. Adherence measurement may include the use of 
subjective measures i.e. self-reporting or objective measures 
such as pill-counts or medication possession ratio (MPR) 
[33]. Self-reporting by the use of any survey instrument was 
acceptable, including AIDS Clinical Trial Group (ACTG) 
adherence questionnaire [34]. The MPR was defined as the 
proportion of prescribed days’ supply obtained from the 
pharmacy during a specified observation period—generally 
the refill interval for a given prescription [35]. Older adults 
were defined as anyone aged 50 years and above. Individuals 
aged between 15 and 50 were categorized as young adults.
Search Strategy and Selection Criteria
The study follows the PRISMA (Preferred Reporting Items 
for Systematic Reviews and Meta-Analyses) guidelines for 
search strategy, which aims to locate all published articles 
on the topic. The databases identified for this review were 
PubMed, Medline, Cochrane CENTRAL, CINAHL, Google 
scholar, and EMBASE, plus reference lists of relevant arti-
cles. The databases searched were based on the keywords: 
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human immunodeficiency virus, antiretroviral therap*, com-
pliance OR adherence, age* (elderly/older adults/adults), 
Africa. The search included all articles published from 1st 
Jan 2000 to 1st March 2016.
Inclusion Criteria
The review considered studies that included people on ART, 
included data on participants aged 50 years and above and 
compared them to a younger cohort, that were conducted in 
Africa and that included data on adherence. We included 
cross-sectional studies, prospective studies, retrospective 
studies, case control studies and randomized control trials. 
We considered studies that covered data on adherence to 
ART using a wide variety of measures. We excluded case 
reports, reviews and publications in languages other than 
English.
Data Extraction and Analysis
The study-screening process adhered to PRISMA recom-
mendations. After duplicates were removed from the inde-
pendent searches, articles were excluded per the identified 
criteria for study selection. It is illustrated in Fig. 1.
Where a screened study made reference to adherence but 
did not present data on adherence rates in that cohort, author 
GF contacted the corresponding author to ask if appropriate 
data were available. Similarly, if a study presented adher-
ence rates that were not stratified into age groups, author GF 
Fig. 1  Prisma flow chart of 
study selection process. *Where 
articles only included children 
or did not include older adults
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contacted the author to assess the possibility of stratifying 
the relevant data.
Data Extraction
Quantitative data was extracted by NS and GF using the 
standardized data extraction tool from JBI-MAStARI [36] 
(Appendix 1). Information was extracted pertaining to study 
title, author names, and publication year, research design, 
and adherence measures. Sample data relating to number of 
participants, follow up periods and number of participants 
(total and in both the older and younger age groups) was col-
lected. The outcome measures extracted were the proportion 
of adherence in the older and younger age groups, recorded 
as number of adherent participants in each group, and pro-
portion of that group who were adherent.
Assessment of Methodological Quality
Given the use of both randomized and non-randomized stud-
ies in our analysis, methodological quality was assessed 
using a modified version of the Downs and Black Frame-
work [37]. Studies were independently scored using 24 
quality criteria. As most studies included in the analysis 
were either cohort studies or cross-sectional studies, ques-
tions pertaining to Randomization or RCTs were excluded 
(Appendix 1 describes the items and their assessment). With 
the exception of one item scored from 0 to 2 points, all items 
were scored as follows: 1 = yes (1 point), – = no (0 points), 
? = don’t know (0 points).
Meta‑analysis
We pooled studies using Comprehensive Meta-Analysis soft-
ware v 3.3.070 (2014). All results were subjected to double 
data entry check. The odds ratio (OR) for each study was cal-
culated and we used a random-effects (DerSimonian-Laird) 
approach for pooling. We examined heterogeneity using the 
 I2 value. We first pooled all randomized trials and then added 
observational studies. We examined differences in treatment 
effects according to study designs.
Results
Study Characteristics
From 968 studies initially identified, 328 were screened for 
detailed evaluation. Between August and November 2016, 
169 authors were contacted, and 22 of those responded to 
provide further information. Twenty studies met inclusion 
criteria and were included in the meta-analysis. Figure 1 pre-
sents the search results and the number of studies extracted 
from research databases. The 20 studies identified for inclu-
sion included eight cohort studies, two retrospective cohort 
studies, five cross-sectional studies, four randomized trials, 
and one case–control study. In terms of geographical area 
six studies used data from Zambia, three from Cote D’Ivoire, 
two each from Uganda, Tanzania, Kenya, and South Africa. 
Table 1 depicts the characteristics of the included studies.
Table 2 describes different adherence measures used in 
the included studies. Adherence was most commonly meas-
ured by patient self-reported questionnaires, or by pill counts 
systems. Two studies calculated MPR, and another two con-
structed an adherence measure based on clinical contact. The 
most frequent definition of adherence was equal or greater 
than 95% compliance with the prescribed regime of ART.
Quality Assessment
Individual study scores are summarized in Appendix 2. 
Studies were considered ‘‘high quality’’ if they scored 60% 
of the maximum score.
Meta‑analysis
The overall cohort of subjects for the 20 included studies 
was 148,819. The pooled data showed that of the 12,401 
older adults, 8947 (72.15%) were considered adherent; and 
of the 136,351 young adults, 92,705 (68.03%) were adher-
ent. The meta-analysis yielded a pooled OR of 1.01 (95% CI 
0.93–1.09), showing no difference in the likelihood of adher-
ence between older and younger adults p = 0.85 (Fig. 2).
Due to the heterogeneity of methods used for measuring 
adherence, a sub-group analysis was conducted by grouping 
subsets of studies that used similar methodology for measur-
ing adherence. Four studies used MPR and clinician counts, 
six used pill counts and seven used self-reports for measur-
ing adherence. When pooled by objective measures of adher-
ence monitoring i.e. MPR and clinician counts, the analysis 
showed significantly higher proportions of adherence among 
older adults compared with their younger peers OR 1.06 
(95% CI 1.02–1.11). However, when data from the six stud-
ies using objective measure of pill counts was pooled, there 
was no difference between the two groups OR 0.84 (95% CI 
0.65–1.09). Meanwhile pooling of studies using subjective 
measure of adherence ‘self-report’ showed no significant 
difference between the older and younger cohorts OR 0.92 
(95% CI 0.72–1.18). Additional sub-group analyses can be 
found in Appendix 3 (Fig. 3).
A further analysis on the effect of study design was 
carried out. The studies were sub-divided into four 
groups, RCTs (4), cross-sectional studies (5), prospec-
tive cohort studies (7) and others (retrospective cohort, 
case–control, etc.) (3). When the data from the four RCTs 
was analysed as a group, the results showed no statistically 
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Table 2  Summary of adherence measures
a AIDS Clinical Trial Group Adherence Questionnaire [34]
Author Adherence measure Adherence cut off
Diabate et al. [67] Self report with ACTG a ≥ 95%
Carlucci et al. [68] Pill count ≥ 95%
Fielding et al. [69] Self report 100% reported adherence in last 3 days
Birbeck et al. [70] Attendance at clinic and self report Attended all scheduled ART clinic visits 
with no lapse in drug collection and 
documentation
Pirkle et al. [71] Self-report N/A
Stubbs et al. [72] Pill count ≥ 90%
Jaquet et al. [73] Self report with ACTG a ≥ 95%
Lester et al. [74] Self report—asked how many pills missed in 30 days ≥ 95%
Watt et al. [75] Self report with ACTG a ≥ 95%
Chung et al. [76] Pill count ≥ 95%
Kunutsor et al. [77] Pill count ≥ 95%
Messou et al. [78] Pill count ≥ 95%
Ncaca et al. [79] Medication possession ratio ≥ 95%
Mbuagbaw et al. [80] Self report using visual analogue scale ≥ 95%
Annison et al. [81] Self report Patients without treatment interruptions
Kiwuwa-Muyingo et al. [82] Pill count and structured questionnaire Good adherence defined as “did not miss 
a dose in last month”
Negash et al. [83] Self report of medication doses taken divided by medication 
doses prescribed 
≥ 95%
Jones et al. [84] Self report using ACTG a Adherence over last two weeks
Vinikoor et al. [39] Medication Possession ratio ≥ 95%
Muya et al. [38] Compliance with pick-up visits ≥ 95%
Fig. 2  Forest plot indicating pooled effect of adherence among older adults compared with younger adults
AIDS and Behavior 
1 3
significant difference between the two groups OR 0.83 (95% 
CI 0.63–1.09). The other results for sub-group analysis based 
on study type were non-significant, cross-sectional studies 
OR 0.89 (95% CI 0.69–1.15), prospective cohort studies [OR 
0.87 (95% CI 0.69–1.01)] the analysis of the other study 
types OR 1.13 (95% CI 0.68–1.89) see Appendix 3. These 
results showed that study design was not an important mod-
erator to affect adherence patterns.
The included studies in the analysis had different weights, 
this weighing is a factor of their sample sizes and variance 
[36.] However, two studies [38, 39] had a very high relative 
weight, forming almost 90% of the pooled results. When 
these studies were excluded the remaining 18 studies showed 
younger adults were more likely to be adherent OR 0.85 
(95% CI 0.73–0.98), p = 0.03 (Appendix 3).
Discussion
Our systematic review shows that ART adherence among 
older people is similar to that of younger people in SSA. 
Despite a general neglect of programs for older adults liv-
ing with HIV in Africa and despite issues of poverty, social 
exclusion, lack of support and mobility challenges, adher-
ence is not statistically different to that of younger people. 
A 2013 meta-analysis by Ghidei and colleagues identified 
12 studies from non-African settings that contained data on 
older adult adherence compared to younger counterparts [7]. 
They found that older age reduced the risk of non-adherence 
by 27% in the studies from the US, Italy, United Kingdom, 
Canada and Brazil. Our study found no such difference in 
their adherence. However, this review included studies that 
used a variety of different measures of adherence each of 
which have their own strengths and weaknesses [40]. For 
example, self-report is a practical tool in low-resource set-
tings, but can overestimate adherence [41]. Pharmacy refill 
adherence measures such as pill counts and calculation of 
the medication possession ratio can be impractical and do 
not measure whether patients are actually taking their medi-
cation, although are less prone to reporting bias than self-
report [42, 43]. Clinical contact measures require a clinician 
to classify adherence as good or poor, and thus subject to 
assessment bias and difficult to standardize [43]. All three 
included measures have been demonstrated to be signifi-
cantly predictive of detectable viremia [44].
We found that when MPR or clinician counts were used 
as the measure of adherence, older adults were more adher-
ent than of younger adults. The reasons for this is unclear; 
however, it could be argued that pharmacy refill-based 
adherence monitoring tools (e.g. MPR) are better adherence 
measures than self-report [45]. It is well accepted that there 
is no gold standard to measure ART adherence [46]. Yet a 
number of available adherence methods such as self-reports, 
pill counts, pharmacy records, self-report electronic moni-
toring, and therapeutic drug levels can be used depending 
on the setting or the available resources. Self-reports and 
pharmacy refill are the most common approaches used in 
Africa due to the low-cost and simplicity. Common limita-
tions include poor sensitivity to detect non-adherence (e.g. 
social desirability bias for self-report or pill dumping for 
pill count) but good specificity for pharmacy refills [42]. 
Therefore, pharmacy refills may accurately capture older 
persons’ adherence behaviour, making it a better measure 
for this population.
Another interesting finding in our analysis was when two 
studies with the largest weights were discounted from the 
pooled analysis, younger adults were significantly more 
adherent than older adults p = 0.03. The key differentiating 
characteristic of these two studies was that their ‘length of 
follow up’ was greater than the other studies i.e. 24 and 
60 months respectively. This may mean that longitudi-
nally older adults may be more likely to be adherent to an 
ART program. Adherence in older adults is complex and 
the next challenge is to better understand the individual, 
Fig. 3  Forest plot indicating sub-group analysis of studies using MPR or clinician contact as adherence measure
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interpersonal, community and structural factors behind 
adherence, and most importantly, the levers by which adher-
ence could be improved. For example, Shubber and col-
leagues’ in a recent systematic review on patient-reported 
barriers identified a number of obstacles including depres-
sion, stigma and health-service related barriers such as dis-
tance from facility [47]. Cultural norms and personal beliefs 
have been acknowledged as key predictors for medication 
adherence in elderly [48]. In the indigenous culture illness is 
sometimes considered as fate, or a condition whose control 
is held by an external locus [49, 50]. These believes com-
bined with the likelihood that older adults living in Africa 
are less likely to be exposed to contemporary western medi-
cine and more likely to have deeper roots in their tradition, 
when compared to their younger counterparts, makes adher-
ence a challenge. A solution to that can be the inclusion 
of patient centred pharmaceutical counselling, this may be 
an important tool to improve their adherence. However, the 
evidence for effectiveness of pharmaceutical counselling 
is from developed countries [51, 52], and may not be eas-
ily translatable in the context of low-resource countries in 
Africa. In these settings, the interaction between physical 
and mental health becomes particularly important [30], and 
future studies should have a special focus on this aspect.
In developed countries older adults show less attrition on 
ART [53], and the CD4 reconstitution is low [54–57], thus 
increasing the importance of early access and strong adher-
ence to reducing mortality. Past studies have explored the 
impact of depression on adherence in Africa [58] as well as 
exploring the impact of community-based adherence inter-
ventions [59–61]. A number of peer-led interventions, such 
as medical companions or support groups for people living 
with HIV, have proven successful in improving ART access 
and adherence in SSA [62, 63] but nearly all exclusively 
target people under 50 years of age [64]. Therefore, prospec-
tive programs need to have a focus on older adults living in 
low-resource or developing countries.
Understanding reasons for late presentation and mecha-
nisms for addressing that shortcoming would be critical to 
improving outcomes among older people. Overall, how-
ever, there have been very limited HIV-related behavioral 
interventions among older people [65] which has limited 
the development of appropriately and specifically targeted 
programs. In order to achieve global HIV goals, the health 
providers must strive to improve the quality of care and qual-
ity of outcomes among all people living with HIV. While 
older adults have long been neglected, there are promising 
signs that their specific needs are now being recognised and 
that appropriate programs will emerge to ensure that older 
people remain productive members of their communities.
Limitations
The diversity of methods used to measure adherence is an 
inherent challenge in systematic review and meta-analysis 
as we have undertaken. Further, the lack of standardised 
conversion of continuous measurements of adherence rates 
into dichotomous or ordinal data weakens any direct com-
parison between different adherence levels across studies. 
Some confounding factors such as chronological age, gen-
der, urban–rural status, overall health, financial status, and 
mobility could not be accounted for while doing the analysis.
The core challenge in this review was that individual stud-
ies varied in their definition and measurement of adherence. 
To deal with this limitation the authors included an addi-
tional variable based sub-analysis, stratified by adherence 
definition. This sub-grouping and pooling of similar stud-
ies may eliminate some confounders for on the variability 
of methodologies among the studies. Similarly, the authors 
acknowledge that dichotomising age may have had implica-
tions on adherence rates. However, the authors ensured that 
the age cut-off used are consistent with the WHO definition 
of older and younger adults in Africa [5]. Another limitation 
may have been the length of follow-up among the studies, 
as shorter studies may have a higher adherence rate than 
longer studies. To understand if there was an effect we ran a 
linear regression analysis between the length of the studies 
and adherence rates, and noted that there was no significant 
difference among the studies due to this variable (β = 0.008, 
p > 0.05) (Appendix 4). Despite literature suggesting that 
adherence changes over time [66], the fact that our analysis 
data didn’t show significance can be attributed to the fact 
that both older and younger adults maintain similar attri-
tion rates and age is not a contributory factor. This further 
supports our results that there is no significant difference in 
among the two age categories.
In the future, studies need to be designed with a standard-
ized measure of adherence in order to improve validity and 
generalizability. The authors further recommend that studies 
track adherence data at set time points, for example every 
three months, this will allow standardized comparison while 
pooling data for future analysis.
Conclusions
This systematic review and meta- analysis found ART adher-
ence levels were similar among older and younger adults 
in Africa. Further research might identify specific barriers 
to adherence in the HIV affected populations, and targeted 
interventions to improve clinical outcomes and quality of 
life when those affected by HIV grow older.
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Appendix 1: Quality Assessment Items
Quality assessment item Maximum points 
awardable
Reporting (9 items)
 Is hypothesis/aims clearly described? 1
 Are the main outcomes to be measured clearly described? 1
 Are the characteristics of the patients included in the study clearly described 1
 Are the interventions of interest clearly described? 1
 Are the distributions of principal confounders in each group of subjects to be compared clearly described? 2
 Are the main findings of the study clearly described? 1
 Does the study provide estimates of the random variability in the data for the main outcomes? 1
 Have all important adverse events that may be a consequence of the intervention been reported? 1
 Have the characteristics of patients lost to follow-up been described? 1
 Have actual probability values been reported (e.g. 0.035 rather than <0.05) for the main outcomes except where the prob-
ability value is less than 0.001?
1
External validity (3 items)
 Were the subjects asked to participate in the study representative of the entire population from which they were recruited? 1
 Were those subjects who were prepared to participate representative of the entire population from which they were 
recruited?
1
 Were the staff, places, and facilities where the patients were treated, representative of the treatment the majority of patients 
receive?
1
Bias (7 items)
 If any of the results of the study were based on “data dredging”, was this made clear? 1
 In trials and cohort studies, do the analyses adjust for different lengths of follow-up of patients, or in case-control studies, is 
the time period between the intervention and outcome the same for cases and controls?
1
 Were the statistical tests used to assess the main outcomes appropriate? 1
 Was compliance with the intervention/s reliable? 1
 Were the main outcome measures used accurate (valid and reliable)? 1
Confounding (6 items)
 Were the patients in different intervention groups (trials and cohort studies) or were the cases and controls (case-control 
studies) recruited from the same population?
1
 Were study subjects in different intervention groups (trials and cohort studies) or were the cases and controls (case-control 
studies) recruited over the same period of time?
1
 Were losses of patients to follow-up taken into account? 1
Power (1 item)
 Does the study describe its calculation of power in order to demonstrate a clinically significant effect? 1
Total 23
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Appendix 2: Quality Assessment Scores
Reporting item Reporting (max 
11 points)
External valid-
ity (max 3 
points)
Bias (max 5 
points)
Confounding 
(max 3 points)
Power (max 1 
point)
Total (max 23 
points)
Total %
Author
 Diabate et al. [67] 8 2 4 1 0 15 65
 Carlucci et al. [68] 8 2 5 2 0 15 65
 Fielding et al. [69] 10 1 5 3 0 17 74
 Birbeck et al. [70] 8 1 5 3 0 15 65
 Pirkle et al. [71] 7 2 5 2 0 14 61
 Stubbs et al. [72] 11 2 5 2 0 18 78
 Jaquet et al. [73] 8 3 5 0 0 16 70
 Lester et al. [74] 10 3 5 3 1 20 87
 Watt et al. [75] 9 1 5 2 0 15 65
 Chung et al. [76] 10 3 5 3 1 20 87
 Kunutsor et al. [77] 9 3 4 3 0 17 74
 Messou et al. [78] 8 2 5 2 0 15 65
 Ncaca et al. [79] 9 3 5 2 0 17 74
 Mbuagbaw et al. [80] 9 2 5 3 1 18 78
 Annison et al. [81] 7 2 5 2 0 14 61
 Kiwuwa-Muyingo et al. 
[82]
10 2 5 3 0 18 78
 Negash et al. [83] 8 2 5 2 1 16 70
 Jones et al. [84] 8 2 5 2 0 15 65
 Vinikoor et al. [39] 8 2 5 3 0 16 70
 Muya et al. [38] 9 2 5 2 0 16 70
Appendix 3: Additional Forest Plots—Sub‑Group Analyses
Analysis of studies using self-report as adherence measure.
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Analysis of studies using pill count as adherence measure.
Analysis excluding two highest weighted studies.
Appendix 4: Linear Regression of Study 
Follow‑Up Period and Adherence Rates
Regression of Log odds ratio on Length
Length of the studies
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